Bayer Decision to Advance IONIS-FXI-LRx for Clotting Disorders
On October 9, 2019 Ionis Pharmaceuticals (IONS) announced it had been notified by its partner Bayer (This content is for paid subscribers.
Bayer Decision to Advance IONIS-FXI-LRx Following Positive Results. See Also: Why Hepion Pharmaceuticals Stock Almost Doubled Today
Today’s Highlights October 17, 2019
Today’s Highlights
October 17, 2019
